	C 2012 Mar 31	2013 Mar 31	C 2014 Mar 31	2015 Mar 31	2016 Mar 31	R 2017 Mar 31	R 2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31	TTM Jun 30
	C 2012 Mar 31	2013 Mar 31	C 2014 Mar 31	2015 Mar 31	2016 Mar 31	R 2017 Mar 31	R 2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31	TTM Jun 30
Period length: Source:	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M IR
Total Revenue	710	608	510	687	653	544	593	457	544	625	661	460	559	559	640	673
Cost of Operating Revenue	491	444	351	406	335	270	301	291	248	305	381	350	341	309	377	338
Gross Profit	219	165	159	281	318	274	292	165	297	320	280	110	218	250	263	335
Gross Margin	30.9	27.1	31.2	40.9	48.7	50.4	49.2	36.2	54.5	51.2	42.3	23.9	38.9	44.7	41.1	49.8
Total Operating Expenses	849	752	651	683	611	539	553	570	503	585	715	566	604	615	672	703
Operating Profit	-139	-144	-141	5	42	5	40	-113	41	39	-54	-106	-45	-56	-33	-30
Operating Margin	-19.5	-23.6	-27.6	0.7	6.5	1.0	6.7	-24.8	7.5	6.3	-8.1	-23.1	-8.1	-10.0	-5.1	-4.5
Financing Income/(Expense) - Net	-110	-95	-145	-128	-126	-108	-105	-120	-170	-183	-177	10	8	8	-1	-6
Profit before Taxes	-255	-253	-111	-99	-19	-52	-64	49	-171	-144	1,449	13	1	-8	-7	-10
Income Taxes	-54	-19	2	3	2	-11	10	8	17	2	371	47	3	1	0	-1
Profit after Tax	-206	-234	-112	-107	-18	-54	-74	38	-194	-148	1,078	-33	-1	-8	-5	-7
PAT Margin	-29.0	-38.5	-22.0	-15.5	-2.8	-10.0	-12.5	8.3	-35.7	-23.6	163.0	-7.2	-0.2	-1.5	-0.8	-1.1
EPS - Basic - ex Extraordinary Items	-33.58	-38.25	-18.31	-17.39	-2.99	-6.40	-11.69	6.69	-30.67	-23.88	175.98	-5.43	-0.19	-1.37	-0.88	-1.16
EPS - Diluted - ex Extraordinary Items	-33.58	-38.25	-18.31	-17.39	-2.99	-6.40	-11.69	6.69	-30.67	-23.88	175.98	-5.43	-0.19	-1.37	-0.88	-1.16
EBIT	-139	-144	-141	5	42	5	40	-113	41	39	-54	-106	-45	-56	-33	-30
EBITDA	-44	-36	-70	72	116	73	98	-59	84	85	-10	-67	-9	-21	0	2
EBITDA Margin	-6.2	-6.0	-13.6	10.4	17.7	13.5	16.6	-13.0	15.5	13.6	-1.5	-14.6	-1.5	-3.8	-	0.3

Balance Sheet

Abridged

Understanding Balance Sheet

Panacea Biotec Ltd. balance sheet covering assets, liabilities, equity and borrowings across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	C 2012 Mar 31	2013 Mar 31	2014 Mar 31	2015 Mar 31	R 2016 Mar 31	R 2017 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	R 2021 Mar 31	R 2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31
	C 2012 Mar 31	2013 Mar 31	2014 Mar 31	2015 Mar 31	R 2016 Mar 31	R 2017 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	R 2021 Mar 31	R 2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31
Source:	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR
Total Current Assets	501	434	381	526	664	700	560	508	683	511	991	568	485	545	513
Long-Term Investments	14	0	0	0	8	7	5	1	1	7	80	0	13	16	18
Property Plant & Equipment - Net	1,199	1,230	1,398	1,260	1,051	1,002	950	812	665	628	626	616	635	637	653
Total Non-Current Assets	1,448	1,406	1,562	1,405	1,139	1,100	1,047	868	707	667	768	703	755	745	749
Total Assets	1,950	1,839	1,943	1,930	1,803	1,800	1,608	1,376	1,390	1,178	1,759	1,271	1,241	1,290	1,262
Total Current Liabilities	517	510	837	706	567	686	691	938	455	449	776	332	309	367	349
Long Term Debt	513	690	583	723	786	714	571	46	613	735	34	20	21	22	24
Total Non-Current Liabilities	552	696	593	752	820	748	611	90	739	960	109	99	94	92	85
Total Liabilities	1,068	1,206	1,430	1,458	1,387	1,434	1,302	1,028	1,195	1,409	885	431	402	459	433
Total Shareholders' Equity	875	626	513	471	404	356	309	350	199	-229	877	844	842	835	835
Minority Interest	7	7	1	1	12	11	-3	-3	-3	-3	-3	-3	-4	-4	-6
Total Equity	882	633	514	472	416	366	306	347	196	-232	874	840	838	831	829
Total Liabilities & Equity	1,950	1,839	1,943	1,930	1,803	1,800	1,608	1,376	1,390	1,178	1,759	1,271	1,241	1,290	1,262

Cash Flow

Abridged

Understanding Cash Flow Statement

Panacea Biotec Ltd. cash flow statement covering operating, investing and financing activities across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	2012 Mar 31	C 2013 Mar 31	C 2014 Mar 31	2015 Mar 31	2016 Mar 31	R 2017 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	C 2024 Mar 31	2025 Mar 31	2026 Mar 31
	2012 Mar 31	C 2013 Mar 31	C 2014 Mar 31	2015 Mar 31	2016 Mar 31	R 2017 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	C 2024 Mar 31	2025 Mar 31	2026 Mar 31
Period length: Source:	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR
Operating CF bef Changes in Working Cap	-122	-182	-142	43	75	-10	-13	-85	33	-10	-796	-78	-1	-14	2
Working Capital - Increase/(Decrease)	288	68	107	-27	-58	43	21	127	-97	22	302	-337	10	-9	14
Net CF from Operating Activities	166	-114	-35	16	17	33	8	42	-64	12	-495	-414	9	-22	16
Capital Expenditures - Net	134	80	51	8	6	24	15	5	-9	18	11	1	76	50	54
Net CF from Investing Activities	-125	-62	-46	-41	15	-28	55	-7	-40	-51	1,279	419	-2	57	-45
Dividends Paid - Cash - Total	5	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Stock - Issuance/(Retirement) - Net	-	-	-	-	-	-	-	-	32	-	-	-	-	-	-
Debt - LT & ST - Issuance/(Retirement) - Total	-55	191	86	24	-75	-8	-55	-35	104	52	-786	-15	0	-	-
Net Cash Flow from Financing Activities	-70	195	67	24	-41	-8	-55	-35	136	52	-786	-15	0	-	3
Free Cash Flow to Equity	-23	-2	1	33	-64	2	-62	3	49	46	-1,292	-431	-67	-72	-38
Free Operating CF net dividend	27	-194	-91	9	5	9	-7	37	-71	-10	-507	-455	-74	-73	-38
Free Operating CF	32	-194	-91	9	5	9	-7	37	-71	-10	-507	-455	-74	-73	-38

Business Segment Analysis

FY End:

Mar 26

Panacea Biotec Ltd. business segment breakdown covering revenue, operating income and assets across key divisions for the selected financial year.

Capex

Vaccine (55.7%)₹ 32.50 CrFormulation (44.3%)₹ 25.89 Cr

Revenue / Sales

Vaccine (64.1%)₹ 410.26 CrFormulation (35.9%)₹ 229.52 Cr

Assets

Vaccine (68.9%)₹ 870.14 CrFormulation (31.1%)₹ 392.03 Cr

Regional Segment Analysis

FY End:

Mar 26

Panacea Biotec Ltd. geographic revenue split showing domestic and international market performance across revenue and income for the selected financial year.

Revenue / Sales

Overseas (65.9%)₹ 421.32 CrDomestic (34.1%)₹ 218.45 Cr

Assets

Domestic (96.0%)₹ 1,212.18 CrOverseas (4.0%)₹ 49.99 Cr

Historical Segment Analysis

Track how Panacea Biotec Ltd. segment contributions have evolved over multiple financial years to see which divisions are growing, shrinking or gaining strategic importance.

Capex

Sales

Assets

Operating Income

Business

Regional

Business

	2010 Mar 31	2011 Mar 31	2012 Mar 31	2013 Mar 31	2014 Mar 31	2015 Mar 31	2016 Mar 31	2017 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31
	2010 Mar 31	2011 Mar 31	2012 Mar 31	2013 Mar 31	2014 Mar 31	2015 Mar 31	2016 Mar 31	2017 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31
Vaccine	26	38	196	38	2	2	5	3	3	0	1	15	10	24	64	30	32
Formulation	10	21	152	13	3	1	2	6	1	1	1	7	4	10	5	8	26
Health Management	0	20	0	0	0	0	0	0	0	-	-	-	-	-	-	-	-
Real Estate	2	0	55	1	1	1	1	0	0	0	0	0	-	-	-	-	-
Research and Development	23	26	73	6	0	1	0	0	0	0	-	-	-	-	-	-	-

Frequently Asked Questions

What is the revenue of Panacea Biotec Ltd.?

The latest trailing twelve month revenue of Panacea Biotec Ltd. is ₹ 672.64 Cr, reflecting a 1-year growth of 10.26% and a 3-year CAGR of 12.03%. Annual and quarterly revenue trends are available in the Income Statement section.

What is the net profit of Panacea Biotec Ltd.?

The latest trailing twelve month net profit (PAT) of Panacea Biotec Ltd. is ₹ -7.22 Cr, with a 3-year earnings CAGR of -30.25%. Detailed profit history across annual and quarterly periods is in the Income Statement section.

What is the EBITDA of Panacea Biotec Ltd.?

The trailing twelve month EBITDA of Panacea Biotec Ltd. is approximately ₹ -39.66 Cr (based on an operating margin of -5.90%). EBITDA reflects core operating profitability before interest, taxes, depreciation and amortisation.

What is the EPS of Panacea Biotec Ltd.?

The trailing twelve month Earnings Per Share (EPS) of Panacea Biotec Ltd. is -1.16. EPS trends across annual and quarterly periods are visible in the Income Statement section.

What is the debt level of Panacea Biotec Ltd.?

The debt-to-equity ratio of Panacea Biotec Ltd. stands at 0.03. The interest coverage ratio is -4.77x, reflecting the company's ability to service debt from operating earnings. The full breakdown of total borrowings is in the Balance Sheet section.

What is the book value per share of Panacea Biotec Ltd.?

The estimated book value per share of Panacea Biotec Ltd. is 136.30 (derived from a P/B ratio of 2.31 and market price of ₹ 314.70), reflecting the net asset value attributable to each share. See the Balance Sheet section for a full breakdown.

What is the cash flow from operations of Panacea Biotec Ltd.?

The trailing twelve month operating cash flow of Panacea Biotec Ltd. is ₹ 16.42 Cr. Annual and quarterly cash flow data is available in the Cash Flow section of the Statements tab.

Does Panacea Biotec Ltd. report consolidated or standalone financials?

Panacea Biotec Ltd. reports consolidated financials. You can toggle between consolidated and standalone views using the switch at the top of each statement section.